-
公开(公告)号：US20120142550A1
公开(公告)日：2012-06-07
申请号：US13311367
申请日：2011-12-05
申请人： James L. Zehnder , Bing Zhang
发明人： James L. Zehnder , Bing Zhang
IPC分类号： C40B30/04 , C40B30/00 , G01N33/566 , C12Q1/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/142 , C12Q2600/158 , G01N2800/7009
摘要： Aspects of the subject invention are drawn to methods, compositions, systems and kits for the assessment of oxidative stress in an individual from a blood sample. In certain embodiments, the expression level of VNN1 in blood cells from a subject (or patient) is assessed and used to determine the subject's oxidative stress state, where an increased/high expression level of VNN1 indicates that the subject is in a state of oxidative stress. Expression of VNN1, and optionally other genes, may be done by assessing nucleic acid and/or protein levels in the blood cells obtained from the subject.
摘要翻译： 本发明的方面涉及用于评估来自血液样品的个体氧化应激的方法，组合物，系统和试剂盒。 在某些实施方案中，评估来自受试者（或患者）的血细胞中VNN1的表达水平并用于确定受试者的氧化应激状态，其中VNN1的增加/高表达水平表明受试者处于氧化态 强调。 可以通过评估从受试者获得的血细胞中的核酸和/或蛋白质水平来进行VNN1和任选的其它基因的表达。
-
2.发明申请MUTATIONS IN THE LNK GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND OTHER HEMATOLYMPHOID MALIGNANCIES 有权LNK基因突变患者与非嗜铬细胞性淋巴瘤和其他HEMATOLYMPHOID恶性肿瘤公开(公告)号：US20120046233A1
公开(公告)日：2012-02-23
申请号：US13005455
申请日：2011-01-12
IPC分类号： A61K38/02 , A61P35/00 , C12Q1/02 , C12Q1/68 , G01N33/566
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
摘要翻译： 本发明的方面包括用于将受试者分类为具有或倾向于血淋巴肿瘤或恶性肿瘤的方法，组合物和试剂盒，如果它们在LNK基因中存在突变。 本发明的方面还包括在基于细胞和无细胞测定中筛选用于治疗基于LNK突变的血液淋巴样肿瘤或恶性肿瘤的候选药物以及用于治疗基于LNK突变体的血淋巴病症的治疗组合物。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。
-
3.发明授权Mutations in the LNK gene in patients with myeloproliferative neoplasms and other hematolymphoid malignancies 有权骨髓增生性肿瘤和其他血液淋巴恶性肿瘤患者LNK基因突变公开(公告)号：US08945846B2
公开(公告)日：2015-02-03
申请号：US13005455
申请日：2011-01-12
CPC分类号： C12Q1/6886 , C12Q2600/136 , C12Q2600/156
摘要： Aspects of the present invention include methods, compositions and kits for classifying a subject as having or being predisposed to a hematolymphoid neoplasm or malignancy if they harbor a mutation in the LNK gene. Aspects of the present invention also include screening for candidate agents for treating LNK mutation-based hematolymphoid neoplasms or malignancies in cell-based and cell free assays as well as therapeutic compositions for treating a LNK-mutant based hematolymphoid disorder. Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods.
摘要翻译： 本发明的方面包括用于将受试者分类为具有或倾向于血淋巴肿瘤或恶性肿瘤的方法，组合物和试剂盒，如果它们在LNK基因中存在突变。 本发明的方面还包括在基于细胞和无细胞测定中筛选用于治疗基于LNK突变的血液淋巴样肿瘤或恶性肿瘤的候选药物以及用于治疗基于LNK突变体的血淋巴病症的治疗组合物。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
